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REVIEW
Abstract: Migraine is a common primary headache disorder often associated with significant
disability. While many individuals are able to limit therapy to acute treatment of attacks,
others need medication to reduce the attack frequency and/or severity. Evidence-based
guidelines exist regarding indications and goals for migraine preventive treatment. The specific
prophylactic approach needs to be individualized taking into account multiple variables.
Medications used in this task vary widely in proven efficacy and presumed mechanisms of
action. This review’s goal is to discuss the issues that guide the decision-making process in
migraine preventive treatment.
Keywords: migraine, prevention, prophylaxis
Introduction
Migraine is a common disabling primary headache disorder. The current International
Classification of Headache Disorders provides diagnostic criteria for up to 7 subtypes
of migraine (IHSCC 2004). In the US, the prevalence is estimated to be 18.2% among
females and 6.5% among males 12 years and older (Lipton et al 2001). Although
studies in general populations agree that many migraineurs have less than 1 attack
per month, in clinical samples the frequency is somewhat higher (Rasmussen and
Stewart 2000). Further, the burden of migraine varies, with some individuals
experiencing many more attacks and associated disability. A recent study identified
620 active migraineurs from the Netherlands’ general population and found that 25%
of them had 2 or more attacks per month (Launer et al 1999). In the US, 35% of
women with migraine experience 1–4 severe attacks a month, and up to 25% of
women experience 4 or more severe attacks a month (Bigal et al 2004). Similar
frequency patterns have been observed in men. The economic and public health
implications of the significant disability, and the reduced work and school productivity
that migraineurs experience can be striking (Lipton et al 2001). Therefore, the
emphasis on proper management for the sufferer clearly is of foremost concern.
Different types of medications are used in the pharmacologic treatment of migraine
and this can be thought of as being acute, preventive, or combined. The optimal
therapeutic approach taken varies depending on each clinical scenario.
Brief overview of current management drug
strategies
Migraine prophylaxis should be considered when one or more of the following are
present: 1) recurring migraines that significantly interfere with the patient’s daily
activities, despite acute treatment; 2) frequent headaches; 3) failure, overuse, or
contraindication of acute treatments; 4) adverse effects of acute treatment; and/or 5)
presence of rare migraine conditions which can potentially cause neurologic damage,
such as hemiplegic migraine, basilar migraine, migraine with prolonged aura, or
migrainous infarction (USHC 2000).
Whereas some patients will require prophylaxis for only brief periods of time
encompassing a predictable triggering situation, most will require long-term treatment.
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Prevention can be viewed as being pre-emptive, short-term
“mini-prophylaxis”, or chronic (daily medication). A good
example of a pre-emptive approach to treatment is the patient
who suffers from migraine headaches triggered by sexual
activity or by exercise. In these settings, single doses of
nonsteroidal anti-inflammatory drugs (NSAIDs) such as
indomethacin administered 1 or 2 hours prior to the known
triggering activities may be effective (Silberstein et al 2002).
Women with pure menstrual migraine in whom, by
definition, migraine headaches are restricted to the
perimenstrual period in at least 2 out of 3 menstrual cycles
(IHSCC 2004), are a good example of an indication for mini-
prophylaxis. The short-term use of triptans or NSAIDs
during the perimenstrual period has shown variable success
rates in this subset of patients (Allais et al 2005).
Evidence-based guidelines are available and have stated
the following goals for migraine preventive treatment: 1)
to reduce attack frequency, severity, and duration; 2) to
improve responsiveness to treatment of acute attacks; and
3) to improve function and reduce disability (USHC 2000).
Additional goals are to decrease costs of migraine
management and perhaps prevent the evolution of episodic
to chronic migraine (Silberstein 2005a).
A variety of medications are used for migraine
prevention, including beta-adrenergic blockers,
antidepressants, anticonvulsants, calcium-channel blockers,
serotonin antagonists (cyproheptadine, methysergide),
NSAIDs, and others (such as, botulinum toxin, atypical
antipsychotics, angiotensin-converting enzyme inhibitors,
selective AT1 subtype angiotensin II receptor antagonists).
When deciding which drug to use, one has to take into
account multiple variables. Ideally, therapy should begin
with a drug that has the highest evidence-based efficacy.
All comorbid–coexistent conditions (existing
simultaneously with and usually independently of migraine)
and all medications being taken for these have to be carefully
reviewed. Pharmaceuticals that can exacerbate migraine
should be identified and discontinued, or changed to a more
acceptable alternative if possible. Migraine prophylactics
that can adversely affect coexisting disorders and cause
unwanted drug interactions should be avoided. Furthermore,
if at all feasible, a preventive should be selected that could
potentially also treat a coexisting condition, if present. For
example, if the migraineur also has hypertension, a beta-
adrenergic blocker may be a reasonable option to treat both
conditions. However, if the migraineur suffers from asthma,
a beta-adrenergic blocker could exacerbate it. Patient
preference should also be considered. Some prophylactics
may either increase or decrease weight and these side-effects
may or may not be desired. Women of childbearing age
should be on adequate contraception during migraine
preventive treatment and migraine prophylaxis with many
of the standard agents should be avoided during pregnancy
to prevent adverse events and/or teratogenicity related to
drugs.
Once a migraine prophylactic has been chosen, therapy
should be started at a low dose of the drug to reduce the
likelihood of side-effects. The dose should be slowly
increased until the desired clinical effect is obtained or until
adverse effects interfere. It is possible that the desired clinical
benefit is not evident until after 2 or 3 months of using the
medication. Therefore, a shorter trial should not be
considered a failure until it has been used for at least that
amount of time. If significant side-effects occur, it may be
necessary to stop the trial. On the other hand, if headaches
are well controlled on a migraine prophylactic agent,
attempts should be made to taper or even discontinue the
medication after 6–12 months of good control. The
minimum effective dose is the goal being sought.
Overall effectiveness of current
approaches
Pre-emptive therapy
Data are limited on the efficacy of pre-emptive treatment
strategies in migraine. Nevertheless, when a known trigger
exists, patients can be recommended to use single doses of




Migraine attacks occurring in the perimenstrual period have
the tendency to be prolonged, intense, and somewhat
resistant to analgesics. Therefore, sufferers from pure
menstrual migraine or menstrually related migraine are ideal
subjects for a short-term migraine prophylaxis. Regular
menstrual periods and predictable attacks are imperative
(Allais et al 2005). Whereas patients with pure menstrual
migraine have attacks only during the perimenstrual period,
those with menstrually related migraine have additional
attacks at other times of the cycle. Drugs proven to be
effective in these settings are NSAIDs, triptans, and
dihydroergotamine (DHE) (Silberstein et al 2001).
Therapeutic doses of NSAIDs such as naproxen sodium
550 mg twice a day starting 1–2 days before the expectedNeuropsychiatric Disease and Treatment 2006: 2(3) 283
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onset of headache and continued through the vulnerable
period can be effective. Other NSAIDs can be tried instead
when the initial choice fails. When gastrointestinal irritation
precludes NSAID use, a cyclo-oxygenase (COX)-2 inhibitor
such as celecoxib 200 mg once a day is a good alternative
when used in the same fashion. A recent abstract suggests
celecoxib decreases the number of migraine days, migraine
attacks, and other acute medication use in menstrually
related migraine (Granella et al 2003).
A study using DHE nasal spray given every 8 hours for
6 days starting 3 days before the headache onset showed a
decreased mean pain severity in 67.5% of 40 patients when
compared with placebo (Silberstein et al 2001). Sumatriptan
was the first triptan to be investigated for mini-prophylaxis.
In an open trial, oral sumatriptan 25 mg 3 times a day starting
2–3 days before headache onset and continued for 5 days
completely prevented pain in 52.4% and decreased the
headache severity by half or more in 42% of 126
sumatriptan-treated cycles of menstrually related migraine
(Newman et al 1998). Naratriptan 1 mg twice a day for 5
days starting 2 days prior to headache onset gave more
headache-free perimenstrual periods, and reduced the
number of menstrually associated migraine days when
compared with placebo (Newman et al 2001); for reasons
that remain unclear, naratriptan 2.5 mg twice daily was not
effective for this purpose. More recently, the same strategy
was applied to pure menstrual migraine. Naratriptan
significantly decreased the mean number of pure menstrual
migraine attacks and decreased the severity of headaches
(Moschiano et al 2005). Frovatriptan’s long half-life and
good tolerability profile might make it attractive for short-
term prophylaxis although the significance of triptan’s half-
life is not entirely understood. At doses of 2.5 mg once or
twice a day for 6 days starting 2 days before the headache
onset, a reduced attack incidence, duration, severity, and
need for rescue medication was seen when compared with
placebo (Silberstein, Elkind, et al 2004). It is important to
note that women with severe menstrual migraine may
respond better to short-term prophylaxis while on a chronic
preventive agent.
Chronic prophylaxis
After extensive evidence-based reviews, the US Headache
Consortium provided evidence-based guidelines regarding
chronic migraine prophylactic drugs (USHC 2000). The
consortium evaluated data available through 1997.
Consisting of medications with proven high efficacy and
mild to moderate adverse effects, group 1 includes
amitriptyline, divalproex sodium, propranolol, and timolol.
Drugs with a lower efficacy and mild to moderate adverse
effects form group 2, including beta-adrenergic blockers
(atenolol, metoprolol, nadolol), calcium-channel blockers
(nimodipine, verapamil), NSAIDs (aspirin, fenoprofen,
flurbiprofen, ketoprofen, mefenamic acid, naproxen,
naproxen sodium), fluoxetine, gabapentin, and others
(feverfew, magnesium, vitamin B2). Group 3 involves
medications with low to moderate side-effects and safety
concerns or complex management issues. This group’s
efficacy was based on opinion (not randomized clinical
trials) and contains antidepressants (bupropion, doxepin,
fluvoxamine, imipramine, mirtazepine, nortriptyline,
paroxetine, protriptyline, sertraline, trazodone, venlafaxine),
others (cyproheptadine, diltiazem, ibuprofen, topiramate),
and phenelzine. Methysergide alone comprises group 4, has
proven efficacy but also safety concerns or complex
management. Finally, composed of drugs proven to have
limited or no efficacy at all, group 5 contains carbamazepine,
clomipramine, clonazepam, clonidine, indomethacin,
nicardipine, nifedipine, and pindolol.
The following section intends to discuss commonly used
chronic prophylactics in the authors’ adult headache practice
(Table 1). Each one is usually tried one at a time as there is
scant scientific evidence of combination therapy efficacy
and two agents often result in more side-effects than a single
agent. Starting doses and range of dosing regimens are
followed by recent evidence (since 2000 guidelines), if any
available, for the particular medication. All of these are
started at a low dose and gradually increased until the
minimal tolerable dose that gives benefit is obtained. Side-
effect profiles are briefly touched on.
Amitriptyline is a tricyclic antidepressant usually given
orally at bedtime secondary to its sedating effect. The usual
starting dose is 10 mg and can be gradually increased by
10 mg per week up to 75 mg or 1 mg/kg body weight (Lance
and Goadsby 2005). It can be particularly useful when
comorbid depression, peripheral neuropathy, or insomnia
is present. Common side-effects are weight gain,
constipation, somnolence, fatigue, and blurred vision in
addition to other anticholinergic events. Use with caution if
at all in epilepsy, glaucoma, and bipolar disorder. Cardiac
dysrhythmias such as tachycardia, changes in
atrioventricular (AV) conduction, and heart block are
potentially serious side-effects. Concomitant use of
monoamine oxidase inhibitors is contra-indicated. When
high doses are used, it can be divided in 1–3 doses.Neuropsychiatric Disease and Treatment 2006: 2(3) 284
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Nortriptyline is a tricyclic antidepressant and a major
metabolite of amitriptyline. It has a more favorable side-
effect profile and is less sedating when compared with the
parent drug. Accordingly, it is frequently prescribed instead
of amitriptyline even though the evidence to support its use
is much less than that for amitriptyline. The starting dose is
10 mg every night and can be gradually increased up to
150 mg a day if needed (Silberstein et al 2001). Nortriptyline
has anticholinergic properties. The side-effects, precautions,
and contraindications are similar to those of amitriptyline.
Propranolol is a nonselective beta-adrenergic blocker
with a usual starting dose of 40 mg a day. This is gradually
increased to a total of 240 mg a day taken in divided doses.
A long-acting form is available with a dose range of 60–
160 mg once a day (Mathew 2005). Patients with coexistent
hypertension, anxiety, mitral valve prolapse, or benign
essential tremor could benefit from its use. Common side-
effects are depression, bradyarrhythmia, fatigue, and
exercise intolerance. Myasthenia gravis and diabetes are
relative contra-indications. Contra-indications include
asthma, congestive heart failure, AV block, and severe sinus
bradycardia.
Atenolol is a cardioselective beta-adrenergic blocker
with a long half-life and a more favorable side-effect profile
compared with propranolol (Silberstein et al 2002). Starting
dose is 50 mg a day and is gradually increased up to 100 mg
a day (in divided doses) if needed (Mathew 2005). Side-
effect profile, precautions, and contraindications are similar
to those of propranolol.
Verapamil is a calcium-channel blocker which could
particularly benefit patients with prolonged focal neurologic
symptoms, or aura (Mathew 2005). However, no solid
evidence exists to support this idea. Nonetheless, verapamil
is effective in migraine prophylaxis although the evidence
base is limited. The dose range starts at 80 mg a day and is
increased as tolerated up to 240 mg a day in divided doses
(Toda and Tfelt-Hansen 2000). Common side-effects are
hypotension, edema, constipation, dizziness, and nausea.
Hypertensive migraineurs can potentially benefit from the
hypotensive side-effect. It is contra-indicated in cardiac
conduction defects, bradycardia, symptomatic hypotension,
and simultaneous beta-adrenergic blocker use.
Divalproex sodium is an antiepileptic. The recommended
oral starting dose is 250 mg taken at bedtime and is gradually
increased, usually by 125–250 mg per week, to a goal dose
of 750 mg per day in 2–3 divided doses (Silberstein 1996).
Higher doses may be needed. The extended-release form is
efficacious, too (Freitag et al 2002), and could potentially
increase compliance since fewer daily doses (once a day)
are required. Divalproex’s initial benefits can be sustained
for prolonged periods of time (Silberstein and Collins 1999).
Certain comorbid epilepsy syndromes could benefit from
divalproex sodium. Hepatic and/or hematologic dysfunction
might occur; therefore, complete blood counts with
differential and liver function tests are obtained prior to
starting therapy and periodically thereafter. Common side-
effects are alopecia, skin rash, weight gain, nausea,
dizziness, somnolence, and tremor. Serious side-effects
include pancreatitis, liver failure, and thrombocytopenia.
Its use during pregnancy or hepatic disease is
contraindicated.
Gabapentin is an anticonvulsant that has been found to
be effective in different pain syndromes such as trigeminal
neuralgia, postherpetic neuralgia, and diabetic neuropathy.
There are two double-blind, placebo controlled-studies
available of gabapentin in migraine prophylaxis. The first
one used a starting dose of 400 mg a day and was increased
by 400 mg every 3 days until a goal dose of 1200 mg a day
Table 1 Commonly used migraine prophylactic medications
Drug Initial dose Typical total daily Common Serious
(mg) dose range (mg) side-effects side-effects
Amitriptyline 10 25–150 Weight gain, constipation, sedation Cardiac dysrhythmias
Nortriptyline 10 25–150 Weight gain, constipation, sedation Cardiac dysrhythmias
Divalproex sodium 250–500 750–1500 Alopecia, weight gain, nausea, tremor Pancreatitis, liver failure,
thrombocytopenia
Propranolol 40–60 40–240 Depression, fatigue Bradyarrhythmia
Atenolol 25 50–100 Depression, fatigue Bradyarrhythmia
Verapamil 80–160 160–480 Edema, constipation Hypotension, dysrhythmias
Gabapentin 300 900–2400 Edema, sedation, fatigue, dizziness
Topiramate 15–25 75–200 Paresthesias, fatigue, weight loss Acute angle closure
glaucoma, hyperthermia,
metabolic acidosis,
nephrolithiasisNeuropsychiatric Disease and Treatment 2006: 2(3) 285
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was reached. With this approach, 30 of 63 patients had a
significative reduction in migraine frequency and intensity
over a 3-month period (Trapani et al 2000). The second study
used a starting dose of 300 mg a day and was gradually
increased up to 2400 mg a day in divided doses. Gabapentin
was superior to placebo in decreasing the median migraine
headache rate over a 12-week period (Mathew et al 2001).
The drug is generally well tolerated. Common side-effects
are peripheral edema, dizziness, somnolence, and fatigue.
Topiramate is another antiepileptic medication used for
migraine prophylaxis which now has an FDA-approved
indication for migraine prevention. A total dose of 100 mg
a day yields similar results to propranolol for reduction in
migraine frequency, migraine days, and daily rescue
medication use according to a placebo-controlled trial using
propranolol as an active control (Diener et al 2004). A double
blind, placebo-controlled study obtained significantly
decreased mean monthly migraine frequency within the first
month of use (Brandes et al 2004). In doses of 100 mg and
up to 200 mg a day, another large controlled trial confirmed
this finding, with topiramate-treated patients exhibiting a
50% or more reduction in monthly migraine frequency when
compared with placebo (Silberstein, Neto, 2004). The
recommended dose starts at 25 mg a day and is gradually
increased by 25 mg a week until the total goal dose of 100 mg
a day (taken as 50 mg twice a day) is achieved (Brandes
2005). In clinical practice, some patients are able to better
tolerate an initial dose of 15 mg and titration in 15 mg
increments. Common adverse events are paresthesias,
fatigue, anorexia, nausea, and weight loss (Silberstein 2004).
Serious side-effects are acute angle-closure glaucoma,
hypohydrosis–hyperthermia, metabolic acidosis, and
nephrolithiasis. Caution is advised in the setting of cognitive
deficits. Based on available data, topiramate is now a first-
line agent in migraine prophylaxis and specifically suits
patients concerned with weight gain, are overweight, or have




Comorbidities, drug interactions, and adverse
effects
Coexistent medical conditions, drug side-effects, and their
interactions may preclude some prophylactics from being
used in specific cases. A careful review of the patient’s
history is essential to avoid injurious outcomes. The previous
section briefly comments on common and serious adverse
effects, precautions, and contraindications of some drugs
but is by no means exhaustive.
Medication overuse
The overuse (> 15 times a month) of combination analgesics,
opioids, ergot alkaloids, and/or triptans for acute migraine
attacks may cause medication overuse headache (Diener et
al 2001). Opioids, butalbital-containing combination
analgesics, and aspirin–acetaminophen–caffeine have the
highest risk for causing this problem, and triptans have
moderate risk (Smith et al 2004). The beneficial effect of
prophylactics can be abolished during the period of acute
symptomatic treatment abuse but can be regained after
successful termination of this behavior (Mathew et al 1990).
One should identify this problem and limit acute treatment
use. Unfortunately, while withdrawing acute analgesics,
headaches may worsen. A short course of prednisone starting
at 60 mg and tapered down over 6 days may offer some
relief during this time (Krymchantowski and Barbosa 2000).
Cost
Cost varies widely among migraine preventive drugs. Not
all patients are able to afford expensive ones. Several
strategies may circumvent this problem, including: a)
utilizing generic forms if available; b) after titration to the
target dose, giving single larger tablets instead of many small
ones; c) use of pill splitting (if it does not affect absorption
of the drug); and d) using medications that treat comorbid
conditions, therefore discarding secondary drugs (Adelman
et al 2004). Knowledge of individual pharmaceutical cost
is imperative to implement prudent and cost-effective
therapeutics.
Oral contraceptives
The influence of oral contraceptives in migraine is
unpredictable. Attacks can start, increase in frequency and
severity, improve, or not change at all in the setting of
initiating oral contraceptive use (Massiou et al 2000).
Approximately a third of women who are adversely affected
improve when the hormones are discontinued (Evans et al
2001). Therefore, in some individuals, this may be needed
as part of the migraine prevention approach. For example,
exogenous estrogen is best avoided in migraine with aura.
Lack of efficacy and tachyphylaxis
Even after proper trials of different prophylactics, the desired
clinical benefit is not always obtained. Moreover, in clinicalNeuropsychiatric Disease and Treatment 2006: 2(3) 286
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practice, tachyphylaxis can be seen after prolonged use of
migraine preventives. Dose adjustments or even a change
of drug may be required (Mathew 2005).
Patient satisfaction
Satisfaction with medical therapeutics has been widely
studied in several disciplines. However, this is not the case
in migraine, where truly, mediators of patient satisfaction
are inadequately understood. Among other factors,
satisfaction results from efficacy, effectiveness, ease of use,
and adverse events (Davies et al 2000). Each individual’s
expectations, perceived performance, and/or disappointment
are of further weight. Expectations of migraineurs from
medications concern their effectiveness, duration of relief,
attack recurrence, ease of use, required doses, side-effects,
time to go back to normal functioning, and efficacy in
relieving associated symptoms (Patrick et al 2003). One
needs to consider all these variables while tailoring each
patient’s treatment plan. Of paramount importance is to
convey reasonable expectations since migraine is a chronic
condition. With effective prophylaxis, approximately two
thirds of patients experience a halving in the number of
attacks.
The care of migraineurs does not always need a
specialist. Nevertheless, primary care physicians may need
to refer the sufferer for headache specialty consultation. A
survey of 281 migraineurs showed significantly improved
satisfaction, and significantly decreased frequency, duration,
and severity of attacks while under headache specialty
management (Hu et al 2000).
Opportunities for new
prophylactic agents – mechanisms
of action, pharmacology, efficacy–
tolerability
Pathophysiology
Although a detailed coverage of migraine pathophysiology
is beyond the goal of this article, it is fundamental to know
a few concepts prior to further discussing possible
mechanisms of action of migraine preventives. Migraine is
a neurovascular reaction to internal and external
environmental changes. The susceptibility for such a
reaction is dictated by the balance between inhibition and
excitation at different levels of the nervous system, and is
influenced by different factors in a given individual (Lance
and Goadsby 2005). Albeit partially understood, it is
postulated that migraine attack vulnerability is based on
neuronal hyperexcitability. An abnormal modulation of brain
nociceptive systems further prolongs head pain (Welch
2003). Possibly, specific acute migraine abortive treatments
exert their main effect at the peripheral neurovascular
system. In contradistinction, preventive medications may
act centrally (Lance and Goadsby 2005), and
nonspecifically, attempting to suppress hyperexcitability
and/or enhance antinociceptive mechanisms (Ramadan
2004). The reason why current prophylactics are effective
in migraine is not known although several hypotheses exist
(Waeber and Moskowitz 2003).
Possible anti-migraine mechanisms of
action of commonly used preventives
Beta-adrenergic blocking drugs may act on the central
catecholaminergic system (Tfelt-Hansen and Rolan 2006).
An event-related, slow, negative cerebral potential known
as contingent negative variation (CNV), believed to be
modulated by this system, tends to normalize after
prophylactic therapy with these drugs. Further, there seems
to be a significant positive correlation between the
potential’s amplitude before treatment onset and clinical
response, with migraineurs with higher amplitudes
benefiting the most (Schoenen et al 1986). Propranolol
diminishes central catecholaminergic activity by inhibiting
norepinephrine release, reduces neuronal activity and
excitability, has membrane-stabilizing properties, and
inhibits nitric oxide production (Ramadan 2004).
Propranolol is highly lipophilic which gives easy access into
the central nervous system (CNS) and therefore has a higher
potential for CNS side-effects such as depression (among
others) when compared with atenolol. If CNS side-effects
preclude or interfere with therapy while on propranolol, a
reasonable option is to change to atenolol which is more
hydrophilic and poorly gets into the CNS (Tfelt-Hansen and
Rolan 2006).
Calcium-channel blockers are a diversified conglomerate
of medications, each one acting at different subtypes of
channels. They most likely act in migraine through their
involvement in CNS neurotransmission (Toda and Tfelt-
Hansen 2006). Nitric oxide derived from perivascular nerves
has been implicated in originating migraine headaches.
Flunarizine decreases calcium influx resulting in decreased
activity of neural nitric oxide synthase (Ayajiki et al 1997).
Evidence suggests that neurogenic inflammation involvingNeuropsychiatric Disease and Treatment 2006: 2(3) 287
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the trigeminal-vascular system participates in migraine
pathogenesis. A study in rats using alpha-eudesmol, a P–Q
type calcium-channel blocker, showed vasoactive
neuropeptide release inhibition and protection against
neurogenic inflammation elicited by trigeminal nerve
activation (Asakura et al 2000). Flunarizine is the most
effective calcium-channel blocker in migraine but is not
available in the US. Verapamil is a good alternative and is
well tolerated (Mathew 2005).
The use of antiepileptic drugs for migraine prevention
is based on the following concept. Migraine and its
associated symptoms may be a result of neuronal
hyperexcitability and if this can be suppressed, further
migraine attacks can be prevented (Welch 2005). Divalproex
sodium is a highly protein-bound fatty acid. Its effect may
result from increased brain gamma-aminobutyric acid
(GABA) which may attenuate migraine-related events at
different levels including the cortex, perivascular
parasympathetics or trigeminal nucleus caudalis (TNC);
from lowered aspartate levels and N-methyl-d-aspartate
(NMDA) receptor activity resulting in attenuated aura
related cortical activity or nociceptive transmission through
the TNC; and from diminished neurogenic inflammation
(Cutrer et al 1997). Topiramate is a D-fructose derivative
containing a sulfamate functionality that readily enters the
CNS (Silberstein and Tfelt-Hansen 2006). Its anti-migraine
properties could result from phosphorylation-mediated
inhibition of voltage gated sodium and calcium channels,
suppression of glutamate-mediated neurotransmission at the
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate
(AMPA)–kainate receptor subtype, enhanced GABA type
A activity, and calcium channel (subtypes L and N) blockade
(Mathew et al 2002; Ramadan 2004). Gabapentin is
structurally related to GABA and readily crosses the blood–
brain barrier (Young et al 2004). It enhances GABA-
mediated inhibition, inhibits GABA metabolism, and
modulates L-type calcium channels by binding to its α2δ
subunit (Cutrer 2001). All three anticonvulsants can cause
mild to moderate side-effects. They may be first-line
preventives when beta-adrenergic blockers or tricyclic
antidepressants are contraindicated or when comorbid
neurologic and/or psychiatric conditions such as epilepsy
or mood disorders are present (Mathew 2001).
Tricyclic antidepressants are lipid-soluble and strongly
bind to plasma proteins. Their antihistaminic and
antimuscarinic activities are responsible for most of their
bothersome adverse effects (Colombo et al 2004).
Amitriptyline inhibits norepinephrine and serotonin uptake
and is the only antidepressant of this class with established
efficacy in migraine prevention. Diffuse noxious inhibition
may be enhanced through this mechanism. Other possible
mechanisms in migraine could be explained by its ability to
block sodium-channels; enhance GABA-mediated
inhibition; potentiate endogenous opioids; and intensify
descending inhibition on nociceptive pathways (Sawynok
et al 2001; Colombo et al 2004; Ramadan 2004).
Antimigraine effects seem to be independent of its
antidepressant influence (Evers and Mylecharane 2006).
Newer agents
The efficacy of multiple preventives from the above
categories has been established (USHC 2000). Since then,
multiple newer drugs have been tried in migraine
prophylaxis. Their efficacy remains to be established in most
cases and their possible mechanisms of action in migraine
remain far from being completely understood.
Botulinum toxin is a potent neurotoxin produced by the
anaerobic bacterium Clostridium botulinum and exists as
seven distinct serotypes (A-G). It causes muscle relaxation
in a dose-dependent fashion at the neuromuscular junction
by blocking acetylcholine release and is currently used to
treat several conditions associated with raised muscle tone
(Ashkenazi and Silberstein 2004). An open-label study using
botulinum toxin type A (Botox
®, Allergan, Inc., Irvine, CA,
USA) suggested it as a safe and effective preventive
treatment in migraine (Binder et al 2000). Three randomized,
double-blind, placebo-controlled studies using Botox
 for
migraine prophylaxis have been performed. The pericranial
injection of 25 units (U) significantly reduced migraine
frequency, migraine severity, acute medication use, and
vomiting over a 3-month period in the first study (Silberstein
et al 2000). The following study showed Botox injection in
the frontal and temporal regions was effective in reducing
pain (Brin et al 2000). Although a trend was seen towards a
reduction in migraine frequency and duration, the study
lacked appropriate statistical power. More recently, the third
study failed to show any efficacy (Evers et al 2004). There
is no consistent evidence yet that Botox
 is effective in
migraine prevention (Evers and Mylecharane 2006),
although this is an area of very active research. If indeed it
helps, its antinociceptive effect likely is not solely explained
by its ability to relax muscle. Several theories for analgesic
mechanisms have been proposed. Botox may: reduce muscle
nociceptor sensitization; act on muscle spindles and theirNeuropsychiatric Disease and Treatment 2006: 2(3) 288
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supraspinal projections indirectly suppressing muscle pain;
decrease neurogenic inflammation; and inhibit substance P
release (Ashkenazi and Silberstein 2004). Further, Botox
could have anti-migraine properties through inhibition of
calcitonin gene-related peptide release from activated
trigeminal sensory neurons (Durham et al 2004). In
migraine, Botox is typically injected in several pericranial
regions using 25–265 U with common doses approximately
100 or 200 U. If beneficial, treatment may be repeated every
3 months since the effect wears off by that time. Side-effects
are usually mild and transient including ptosis, frontal
weakness, and local pain at the injection site (Ramadan
2004).
Candesartan is a long-acting angiotensin II receptor
blocker with high affinity for the AT1 receptor. A
randomized, double-blind, placebo-controlled crossover
study done with 60 adult patients suffering 2–6 migraine
attacks per month used 16 mg once a day. Over a period of
12 weeks, patients treated with candesartan experienced 13.6
headache days compared with 18.5 in the placebo group.
Further, candesartan was favorable in terms of hours with
headache, days with migraine, hours with migraine,
headache severity index, level of disability, and days of sick
leave. No differences were seen in terms of health-related
quality of life. The drug tolerability profile was similar to
that of placebo (Tronvik et al 2003). Candesartan could exert
its anti-migraine properties through a decrease in glutamate
release and enhancement of GABA mediated inhibitory tone
(Goadsby and Ramadan 2006).
Lisinopril is an angiotensin converting enzyme (ACE)
inhibitor. A double-blind, placebo-controlled crossover
study done with 60 adult patients suffering 2–6 migraine
attacks per month used a starting dose of 10 mg once a day
for a week followed by a goal dose of 20 mg once a day.
Over a period of 12 weeks, days with migraine were reduced
by at least 50% in 14 of 47 patients that completed data.
Hours with headache, days with headache, days with
migraine, and headache severity index were significantly
reduced with lisinopril compared with placebo (Schrader et
al 2001). The drug was well tolerated. Side-effects included
dizziness, tendency to faint, and cough. Of particular interest
is a recent study suggesting men with the homozygote DD
genotype of the ACE gene may be protected against migraine
(Lin et al 2005). These men seem to have higher levels of
circulating ACE activity.
Zonisamide is a modern anticonvulsant with a long half-
life permitting once-a-day dosing. A recent open-label study
for refractory migraine used a starting dose of 100 mg a day
and was gradually increased to 400 mg a day. Statistically
significant improvements were seen by 1 month for
headache severity, duration, and frequency and persisted
through the 3-month period studied (Drake et al 2004). The
drug was well tolerated for the most part with only transient
and tolerable side-effects including paresthesias, fatigue,
anxiety, weight loss, weight gain, and nausea. However,
11.8% of patients discontinued the drug secondary to
dysphoria and difficulty with concentration.
Multiple other pharmaceuticals including but not limited
to those acting on brain energy metabolism such as
coenzyme Q10, magnesium, and riboflavin have been
tried.
Opportunities for future agents
The understanding of migraine pathophysiology continues
to evolve. While several prophylactics have proven efficacy
and multiple others are being actively tried, the mechanisms
of action remain speculative. As migraine’s pathophysiology
and current drug mechanisms including the above described
are better understood, newer agents are likely to emerge.
One hypothesis is the following. Cortical spreading
depression (CSD) is a phenomenon believed to be similar
to the human migraine aura. Whether migraine aura
indirectly produces pain is still controversial. If it does, drugs
that could block this process would potentially be useful
and such agents exist (Goadsby and Ramadan 2006).
Currently, acute treatment that targets different receptors
mediating the multiple neurochemical reactions leading to
individual migraine attacks is a very active area of research.
Points of interest in this chain of events besides CSD
inhibition include the: inhibiting mechanism of
neurovascular coupling neurogenic inflammation;
inhibition of nociceptor activation; enhancement of
descending modulation; and blocking of peripheral and
central sensitization (Ramadan 2005). There is evidence
to support that calcitonin gene-related peptide (CGRP)
receptor antagonism, adenosine A1 receptor agonism,
AMPA–kainate antagonism, and vanilloid receptor
manipulation could translate into new acute abortive
treatments (Goadsby 2004; Sang et al 2004). However,
whether such new knowledge could transpose also into the
development of new migraine prophylactics is yet to be
seen. Opioid receptor-like-1 and arachidonylethanolamide
(anandamide) are other receptors that, although less
understood at this time, may play a role in future migraine
therapy (Goadsby 2004).Neuropsychiatric Disease and Treatment 2006: 2(3) 289
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Future management strategies in
migraine combining prophylaxis
and acute management
A combined migraine treatment plan that considers
avoidance of triggering factors, acute symptomatic
treatment, and prophylaxis is indispensable to obtain
maximum long-term benefit (D’Amico 2004). While
preventives are aimed at containing the incidence and
vulnerability to attacks, episodic acute treatment is of
paramount importance to reduce migraine-related disability
during those episodes. A critical step in the prolonged
management of migraineurs is to prevent medication overuse
headache, which can render prophylactics ineffective. This
is a common problem seen in specialty headache practice.
A reasonable rule of thumb to avoid this problem is to limit
acute symptomatic treatment such as triptans, among others,
to not more than 2 days a week (9 days per month) on
average. Through a decrease in need for acute treatment,
preventives assist in accomplishing this goal.
Other special settings that markedly benefit from
combination therapy are those of menstrual migraine and
menstrually related migraine. Attacks during this period can
be particularly difficult to treat and may not respond to acute
analgesics (Allais et al 2005). Women with severe menstrual
migraine often respond better to acute treatment while on a
chronic prophylactic agent (Silberstein et al 2001).
Consequently, combined chronic preventive with a short-
term prophylaxis during the vulnerable period is a logical
approach in some of these patients.
The possibility that timely prophylaxis may impede
progression to a more chronic and more treatment resistant
migraine disorder is currently being entertained (Loder and
Biondi 2005). The role of a combined approach in preventing
this progression remains to be known. This thought,
however, once again accentuates the relevance and
importance of migraine prophylaxis.
Conclusions
Migraine is a common disabling primary headache disorder
associated with significant disability. Evidence-based
guidelines are available regarding indications and goals for
migraine preventive treatment (USHC 2000). The specific
prophylactic approach needs to be individualized after
multiple variable considerations in order to raise the odds
of success and to prevent injurious outcomes. Medications
used in this task vary widely in proven efficacy. Their anti-
migraine mechanisms of action are not entirely understood
and remain speculative to this date. Awareness of therapy
limitations is crucial to prevent drawbacks in the overall
goals established. Migraine’s pathophysiology and natural
history understanding is evolving. Higher quality
medications and preventive approaches should be
forthcoming as our knowledge on migraine and the
medications we currently use in its treatment increase.
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